Recent clinical research examines the impact of SGLT-2 inhibitors cancer risk among individuals living with type 2 diabetes. This large-scale retrospective cohort study compared patients starting sodium-glucose co-transporter 2 inhibitors (SGLT-2i) with those initiating dipeptidyl peptidase-4 inhibitors (DPP-4i). By utilizing real-world data from the TriNetX US Collaborative Network, investigators aimed to determine if these glucose-lowering agents influence obesity-associated malignancies.

Notably, the initiation of SGLT-2 inhibitors did not show a significant association with composite obesity-associated cancers compared to DPP-4i. However, the study revealed distinct findings for specific cancer types within the overall population. For instance, SGLT-2i users experienced a 22% lower rate of renal cancer. Conversely, researchers observed a 37% higher rate of thyroid cancer in the same group. Consequently, these findings suggest that the relationship between drug class and malignancy is nuanced and site-specific.

Evaluating SGLT-2 Inhibitors Cancer Risk in Clinical Practice

Furthermore, the analysis demonstrated modest reductions in the all-cancer outcome for the overall diabetic population. This trend remained consistent among individuals regardless of their overweight or obesity status. While the clinical significance of these overall reductions remains unclear, the potential for protective effects against certain tumors is an area for future investigation. Therefore, clinicians must balance metabolic benefits with long-term safety profiles when selecting second-line therapies.

In conclusion, while SGLT-2 inhibitors appear safe regarding the broad category of obesity-related cancers, the observed variations in renal and thyroid cancer rates warrant attention. This real-world evidence provides a deeper understanding of how modern diabetes medications interact with oncological risks in high-risk populations.

Frequently Asked Questions

Does using SGLT-2 inhibitors increase the risk of obesity-related cancers?

No, this large-world study found that SGLT-2 inhibitors were not associated with higher or lower rates of composite obesity-associated cancers when compared with DPP-4 inhibitors.

Which cancers showed a changed incidence rate with SGLT-2 inhibitors?

The study reported a lower rate of renal cancer (HR 0.78) but identified a higher rate of thyroid cancer (HR 1.37) in patients initiating SGLT-2 inhibitors compared to those on DPP-4 inhibitors.

Was there any benefit observed for overall cancer risk?

Yes, researchers noted a modest reduction in the all-cancer outcome among the general cohort and those with overweight or obesity who initiated SGLT-2 inhibitors.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional opinion. Readers should consult with a qualified healthcare professional regarding any medical concerns or treatments. Refer to the latest local and national guidelines for clinical practice.

References

Ipaye T et al. Sodium-glucose co-transporter 2 inhibitors and obesity-associated cancers in people with type 2 diabetes: A real-world observational study. Diabetes Obes Metab. 2026 Feb 26. doi: 10.1111/dom.70562. PMID: 41749411.

Zheng J et al. Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis. Diabetol Metab Syndr. 2025 Aug 07.

Wang Y et al. Impact of SGLT2 Inhibitors on Tumor Development Risk in Type 2 Diabetes. Drug Des Devel Ther. 2025 Dec 15.